Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Agile Therapeutics, Inc.

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Announces Delisting from Nasdaq
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Tickers AGRX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.